Maternal whole blood mRNA signatures identify women at risk of early preeclampsia: a longitudinal study
- 3 January 2020
- journal article
- research article
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 34 (21) , 3463-3474
Abstract
Purpose: To determine whether previously established mRNA signatures are predictive of early preeclampsia when evaluated by maternal cellular transcriptome analysis in samples collected before clinical manifestation. Materials and methods: We profiled gene expression at exon-level resolution in whole blood samples collected longitudinally from 49 women with normal pregnancy (controls) and 13 with early preeclampsia (delivery untargeted cellular mRNA signature was higher in women diagnosed with early preeclampsia at 32–34 weeks of gestation, yet more importantly, also prior to diagnosis at 28–32 weeks and 22–28 weeks of gestation, compared to controls (all, p < .05). (2) A combination of four genes from this signature, including a long non-protein coding RNA [H19 imprinted maternally expressed transcript (H19)], fibronectin 1 (FN1), tubulin beta-6 class V (TUBB6), and formyl peptide receptor 3 (FPR3) had a sensitivity of 0.85 (0.55–0.98) and a specificity of 0.92 (0.8–0.98) for prediction of early preeclampsia at 22–28 weeks of gestation. (3) H19, FN1, and TUBB6 were increased in women with early preeclampsia as early as 11–17 weeks of gestation (all, p < .05). (4) After diagnosis at 32–34 weeks, but also prior to diagnosis at 11–17 weeks, women destined to have early preeclampsia showed a coordinated increase in whole blood expression of several single-cell placental signatures, including the 20-gene signature of extravillous trophoblast (all, p < .05). (5) A combination of three mRNAs from the extravillous trophoblast signature (MMP11, SLC6A2, and IL18BP) predicted early preeclampsia at 11–17 weeks of gestation with a sensitivity of 0.83 (0.52–0.98) and specificity of 0.94 (0.79–0.99). Conclusions: Circulating early transcriptomic markers for preeclampsia can be found either by untargeted profiling of the cellular transcriptome or by focusing on placental cell-specific mRNAs. The untargeted cellular mRNA signature was consistently increased in early preeclampsia after 22 weeks of gestation, and individual mRNAs of this signature were significantly increased as early as 11–17 weeks of gestation. Several single-cell placental signatures predicted future development of the disease at 11–17 weeks and were also increased in women already diagnosed at 32–34 weeks of gestation.Keywords
Funding Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institutes of Health
- US Department of Health and Human Services
- NICHD/NIH/DHHS
- Wayne State University School of Medicine
This publication has 71 references indexed in Scilit:
- Differentially Expressed Genes in the Pre-Eclamptic Placenta: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trialUltrasound in Obstetrics & Gynecology, 2011
- The “Great Obstetrical Syndromes” are associated with disorders of deep placentationAmerican Journal of Obstetrics and Gynecology, 2011
- Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsiaJournal of Perinatal Medicine, 2011
- A framework for oligonucleotide microarray preprocessingBioinformatics, 2010
- Metabolomics in premature labor: a novel approach to identify patients at risk for preterm deliveryThe Journal of Maternal-Fetal & Neonatal Medicine, 2010
- Proteomic profiling of amniotic fluid in preterm labor using two-dimensional liquid separation and mass spectrometryThe Journal of Maternal-Fetal & Neonatal Medicine, 2008
- The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational ageThe Journal of Maternal-Fetal & Neonatal Medicine, 2008
- A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonateThe Journal of Maternal-Fetal & Neonatal Medicine, 2008
- The use of high‐dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndromeBJOG: An International Journal of Obstetrics & Gynaecology, 2006